Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Satiasolv
- Development stage
- Preclinical
- Lead developer
- Marinomed Biotech
- Modality
- Small Molecules
- Administration
- Intranasal, Oral
01
Overview
Satiasolv (MAM-1018-1) is a preclinical-stage small molecule therapeutic being developed by Marinomed Biotech AG. It is a water-based formulation of cannabidiol (CBD) that utilizes the company's proprietary Marinosolv technology platform to enhance the solubility and bioavailability of the lipophilic active ingredient. Satiasolv is intended for nasal and/or oral administration to treat various inflammatory conditions of the nose and mouth, as well as metabolic disorders. The mechanism of action is based on the anti-inflammatory and metabolic modulatory properties of cannabidiol, although specific molecular targets for this formulation have not been detailed by the developer.
- Brand names
- Satiasolv
- Other names
- cannabidiol
Beyond the preview
Go deeper on Satiasolv.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Satiasolv.